Cancer drug marches toward filing

Share this article:

Merrimack Pharmaceuticals said today that its candidate for metastatic pancreatic cancer, MM-398, in combination with 5-FU and leucovorin, met its primary endpoint and will be submitted to the FDA in 2014. The agency granted MM-398 an orphan drug designation for metastatic pancreatic cancer in 2011.

MM-398+5-FU+leucovorin saw an overall survival of 6.1 months, representing a 1.9-month improvement over the 4.2 months of survival demonstrated by a control arm of 5-FU+leucovorin alone. MM-398, on its own, did not demonstrate a statistically significant survival advantage, though.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.